GlassScriptPhysician profile
Matthew Jepson
NPI 1669883740
$3,235.72
in general payments reported to CMS, 2019-2025
28 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $575 · 2021: $656 · 2022: $536 · 2023: $462 · 2024: $359 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $699.20 | 2019-2024 | |
| Abbott Laboratories | $495.81 | 2020-2025 | Jot Dx, Aveir, Cardiomems |
| Pfizer INC. | $339.25 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $290.01 | 2020-2024 | Xarelto |
| Boston Scientific Corporation | $209.97 | 2019-2025 | Watchman Access System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $187.55 | 2019-2022 | |
| Amgen INC. | $166.88 | 2020-2025 | Repatha, Repatha |
| Heartflow, INC. | $144.30 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $118.30 | 2022-2024 | Eliquis |
| Scpharmaceuticals INC. | $79.10 | 2023-2025 | |
| Amarin Pharma, INC. | $72.13 | 2019-2021 | |
| Integra Lifesciences Corporation | $53.60 | 2020 | |
| Philips North America LLC | $42.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.70 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $32.11 | 2022-2025 | Lokelma |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $31.08 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $26.95 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $26.58 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $24.84 | 2024 | Onpattro |
| Cvrx, INC. | $23.37 | 2022 | |
| Medtronic Vascular, INC. | $22.00 | 2020 | |
| Atricure, INC. | $19.85 | 2023 | |
| Outset Medical INC | $19.21 | 2023 | |
| Sobi, INC | $17.48 | 2022 | |
| Merck Sharp & Dohme LLC | $16.56 | 2025 | Winrevair |
| Medtronic, INC. | $14.45 | 2021 | |
| Esperion Therapeutics, INC. | $13.32 | 2023 | Nexletol |
| Teleflex LLC | $12.93 | 2023 | Vascband |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Jepson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.